Charles Mcwherter Sells 21,749 Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Stock

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) insider Charles Mcwherter sold 21,749 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $9.08, for a total value of $197,480.92. Following the completion of the transaction, the insider now owns 15,000 shares in the company, valued at $136,200. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

CymaBay Therapeutics Stock Performance

NASDAQ CBAY opened at $9.11 on Friday. The business’s fifty day moving average is $9.51 and its 200 day moving average is $7.22. The company has a market capitalization of $888.32 million, a PE ratio of -7.72 and a beta of 0.27. CymaBay Therapeutics, Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $11.22.

CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) last issued its earnings results on Thursday, March 16th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.30). During the same period in the prior year, the company posted ($0.34) EPS. On average, sell-side analysts forecast that CymaBay Therapeutics, Inc. will post -1.01 EPS for the current year.

Hedge Funds Weigh In On CymaBay Therapeutics

Institutional investors have recently bought and sold shares of the stock. Great West Life Assurance Co. Can purchased a new position in CymaBay Therapeutics during the first quarter valued at $40,000. Dorsey Wright & Associates bought a new position in CymaBay Therapeutics during the fourth quarter valued at $39,000. Royal Bank of Canada lifted its position in CymaBay Therapeutics by 506.5% during the third quarter. Royal Bank of Canada now owns 7,581 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 6,331 shares during the last quarter. Victory Capital Management Inc. bought a new position in CymaBay Therapeutics during the first quarter valued at $88,000. Finally, CTC Capital Management LLC bought a new position in CymaBay Therapeutics during the first quarter valued at $93,000. 73.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CBAY has been the topic of a number of research reports. SVB Leerink raised their price target on CymaBay Therapeutics from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 8th. Cantor Fitzgerald raised their price target on CymaBay Therapeutics from $13.00 to $15.00 in a research note on Tuesday, May 16th. BTIG Research initiated coverage on CymaBay Therapeutics in a research note on Thursday, March 9th. They issued a “buy” rating and a $15.00 price target on the stock. William Blair initiated coverage on CymaBay Therapeutics in a research note on Wednesday, April 5th. They issued an “outperform” rating on the stock. Finally, Piper Sandler lifted their target price on CymaBay Therapeutics from $12.00 to $19.00 and gave the company an “overweight” rating in a research report on Sunday, January 29th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.57.

About CymaBay Therapeutics

(Get Rating)

CymaBay Therapeutics, Inc engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.